NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

September 2022

7:30am – 4:00pm

Earn up to 7 AMA PRA Category 1 Credits,™ Continuing Nursing Education (CNEG), and MOC accreditation





Jointly Provided by the University of Pennsylvania and the North American Neuroendocrine Tumor Society

Course Director

Lowell Anthony, MD, University of Kentucky


Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment and management of NETs are time-consuming, complex and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors


7:30-8:00 am
8:00-8:10 am
Registration and Breakfast
Welcome and Opening Remarks
    • Mark Evers, MD, FACS – Prof of Surgery, Director, Markey Cancer Center, University of Kentucky
    • Lowell B. Anthony, MD, FACP - Prof of Medicine, University of Kentucky
8:10-9:30 am
Overview of Neuroendocrine Tumors
    • Background, Epidemiology, Natural History, Clinical Features – Lowell B. Anthony, MD, FACP, Professor of Medicine, University of Kentucky
    • Imaging for Diagnosis and Disease Surveillance – Riham El-Khouli, MD, PhD, Associate Professor of Radiology & Director of Theranostics, University of Kentucky
    • Pathology of NETs: General features, classification – Sahar Nozad, MD, Assistant Professor of Pathology, University of Kentucky
9:30-10:45 am
Surgical Treatment of NETs
    • Surgical Principles for Early Stage NETs – Michael Cavnar, MD, Assistant Professor of Surgery, University of Kentucky
    • Management of Metastatic NETs: Role of Debulking Surgery – James Howe, MD, Professor of Surgery, University of Iowa
    • Panel: Q/A (all above)
10:45-11:00 am
11:00-11:40 am
Keynote-1 Role of Radiopharmaceuticals in NETs
    • Charles Kunos, MD, PhD, Medical Officer, Investigational Drug Branch of the Cancer Therapy Evaluation Program of Radiation Branch, NCI Bethesda, MD
11:40-11:55 am
Radioisotopic Targeting of NETS: Lutetium-177 dotatate and I-131 MIBG
    • Aman Chauhan, MD, Assistant Professor of Medicine & Director of NET Theranostics, University of Kentucky
11:55-12:10 pm
Panel:  Q/A (All above)
12:10-1:00 pm
1:00 – 2:00 pm
Medical Management of NETs
    • Functional NETS, Complications and Hormonal Management – Thomas O’Dorisio, MD, Professor Medicine, University of Iowa
    • Carcinoid Heart Disease: Management and Future Direction – Heloisa Soares, MD, Associate Professor, University of Utah
    • FDA Approved Therapies for NETs – Daneng Li, MD, Assistant Professor of Medical Oncology and Co-director of NET Program, City of Hope, Duarte, California
2:00-2:20 pm
Local Regional Therapies 
    • Hepatic Transarterial Therapies: What the Interventional Oncologic Radiologist Can Offer – Michael Soulen, MD, Professor of Radiology, University of Pennsylvania
    • Case Presentations - Gaby E. Gabriel, MD, Assistant Professor of Radiology, University of Kentucky
2:20-2:30 pm
Panel:  Q/A (All above)
2:30-3:10 pm
Keynote-2, Current Landscape of NET Clinical Trials and Future Direction
    • Elise Kohn, MD, Head, NET Therapeutics, NCI, Cancer Therapy Evaluation Program, NCI Bethesda, MD
3:10-3:40 pm
 Thoracic NETs
    • Surgical Management of Bronchial Carcinoids – Jordan Miller, DO, Assistant Professor of Surgery, University of Kentucky
    • Medical Management of Thoracic NETs – Satya Nanu Das, MD, Assistant Professor of Medicine, Vanderbilt University
3:40-3:50 pm
Overview of Markey NET Multi-Disciplinary Program
    • Aman Chauhan, MD, Assistant Professor of Medicine & Director of NET Theranostics, University of Kentucky
3:50-4:00 pm
Concluding Remarks and High Tea
    • Lowell B. Anthony, MD, FACP, Professor of Medicine, University of Kentucky
    • Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of CMEsolutions and North American Neuroendocrine Tumor Society. The CMEsolutions is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The CMEsolutions designates this live activity for a maximum of AMA PRA Category 1 Credits.™  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been submitted to the Continuing Nursing Education Group, for approval to award nursing contact hours. The Continuing Nursing Education Group is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. 



In-person registration is available onsite the day of the program and will be accommodated on a space-available basis

Registration fee:


$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident


$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before April 19, 2020. On or after April 20, 2020, no refund will be made.

The University of Kentucky and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.


Please contact us with any questions.